Nexera Pharma has received a $3.6 million (approximately \u00a5565 million) milestone from Centessa and plans to record it as revenue in the fourth quarter of the fiscal year ending December 2025.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nexera Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-01-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4565-20260113-01.pdf","jir_short_summary":"Nexera Pharma has received a $3.6 million (approximately \u00a5565 million) milestone from Centessa and plans to record it as revenue in the fourth quarter of the fiscal year ending December 2025.","jir_summary":"### Overview of Milestone Receipt\nNexera Pharma Co., Ltd. has received $3.6 million (approximately \u00a5565 million) following the achievement of an early development milestone for ORX142, an orexin receptor 2 (OX2R) agonist under development by partner Centessa Pharmaceuticals Limited. This amount will be recorded as revenue in the fourth quarter of the fiscal year ending December 2025.\n\n### Company Overview and Pipeline\nNexera Pharma is a technology-driven biopharmaceutical company developing a pipeline of over 30 products in-house and with partners using the NxWave\u2122 drug discovery platform. The company focuses mainly on obesity and metabolic disorders, neurological and neuropsychiatric disorders, as well as immune and inflammatory diseases, and operates globally.","jir_financial_highlights":"Milestone Amount Received: $3.6 million (approximately \u00a5565 million) (Unknown)\nRevenue Recognition Period: Fiscal Year Ending December 2025 Q4 (Unknown)","jir_category":"","jir_hashtags":"#NexeraPharmaCoLtd, #business_update, #biopharmaceuticals","jir_key_figures":"Milestone Amount Received: $3.6 million (approximately \u00a5565 million)\nRevenue Recognition Period: Fiscal Year Ending December 2025 Q4\nPartner: Centessa Pharmaceuticals Limited","jir_meta_title":"Nexera Pharma Announces Receipt of $3.6 Million Milestone from Centessa","jir_meta_description":"Nexera Pharma Co., Ltd. has received a $3.6 million (approximately \u00a5565 million) milestone from partner Centessa Pharmaceuticals Limited, to be recorded as revenue in the fourth quarter of the fiscal year ending December 2025.","jir_og_title":"Nexera Pharma Receives $3.6 Million Milestone from Centessa","jir_og_description":"Nexera Pharma received $3.6 million following the early development milestone achievement for Centessa's drug ORX142.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16879,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-18757","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n